Kidney stones prevalence reaches 4.3% among cat5 deletion carriers, in-between estimates for larger cat1-4 deletion carriers (9.2%) and copy-neutral individuals (2.3%) (Fig. 5E). This evidence concerns the gene COQ7 and nephrolithiasis.